Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (RINDO study).

Hattori, M; Hattori, N; Nakayama, G; Umeda, S; Kishida, T; Kawase, Y; Ezaka, K; Tsutsuyama, M; Sakai, M; Ito, T; Yanbe, Y; Kanda, M; Tanaka, C; Murotani, K; Ando, M; Kodera, Y

JOURNAL OF CLINICAL ONCOLOGY   Vol. 43 ( 4_SUPPL ) page： 124 - 124   2025.2